

# BLADDER CANCER TREATMENT AND RECURRENCE ALGORITHMIC TESTS

- I. The use of bladder cancer treatment and recurrence algorithmic test (0013M, 0016M, 0363U, 0366U, 0367U) is considered **medically necessary** when:
  - A. The member has a diagnosis of bladder cancer, **AND**
  - B. Results of algorithmic testing will affect management decisions for the member's bladder cancer, **AND**
  - C. The member has not previously undergone bladder cancer treatment and recurrence algorithmic testing for the current cancer diagnosis.
- II. The use of bladder cancer treatment and recurrence algorithmic test (0013M, 0016M, 0363U, 0366U, 0367U) is considered **investigational** for all other indications.

## REFERENCES

1. Centers for Medicare & Medicaid Services., Dep't of Health & Human Services ("CMS"), Medicare Coverage Database: Local Coverage Determination "MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer" (L38576). Available at:  
<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38576>